Qurient Co. Ltd (115180) - Cash Flow Conversion Efficiency

Latest as of September 2025: -0.062x

Based on the latest financial reports, Qurient Co. Ltd (115180) has a cash flow conversion efficiency ratio of -0.062x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-3.15 Billion ≈ $-2.13 Million USD) by net assets (₩50.69 Billion ≈ $34.35 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Qurient Co. Ltd - Cash Flow Conversion Efficiency Trend (2014–2024)

This chart illustrates how Qurient Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read 115180 liabilities breakdown for a breakdown of total debt and financial obligations.

Qurient Co. Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Qurient Co. Ltd ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Zhejiang Changhua Auto Parts Co Ltd
SHG:605018
0.048x
Eczacibasi Yatirim Holding Ortakligi AS
IS:ECZYT
0.001x
Varroc Engineering Limited
NSE:VARROC
0.212x
Minerals 260 Ltd
AU:MI6
-0.038x
Aucma Co Ltd
SHG:600336
0.257x
Qingdao Eastsoft Communic Tech
SHE:300183
0.004x
People & Technology Inc
KQ:137400
0.023x
SMU S.A
SN:SMU
0.071x

Annual Cash Flow Conversion Efficiency for Qurient Co. Ltd (2014–2024)

The table below shows the annual cash flow conversion efficiency of Qurient Co. Ltd from 2014 to 2024. For the full company profile with market capitalisation and key ratios, see market cap of Qurient Co. Ltd.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 ₩57.60 Billion
≈ $39.03 Million
₩-23.32 Billion
≈ $-15.80 Million
-0.405x +14.10%
2023-12-31 ₩46.62 Billion
≈ $31.59 Million
₩-21.97 Billion
≈ $-14.89 Million
-0.471x +33.78%
2022-12-31 ₩35.14 Billion
≈ $23.81 Million
₩-25.00 Billion
≈ $-16.94 Million
-0.712x -57.89%
2021-12-31 ₩54.08 Billion
≈ $36.65 Million
₩-24.37 Billion
≈ $-16.52 Million
-0.451x -28.45%
2020-12-31 ₩56.57 Billion
≈ $38.33 Million
₩-19.85 Billion
≈ $-13.45 Million
-0.351x +74.59%
2019-12-31 ₩17.38 Billion
≈ $11.78 Million
₩-24.00 Billion
≈ $-16.26 Million
-1.381x -294.23%
2018-12-31 ₩39.41 Billion
≈ $26.70 Million
₩-13.80 Billion
≈ $-9.36 Million
-0.350x +59.55%
2017-12-31 ₩14.53 Billion
≈ $9.85 Million
₩-12.59 Billion
≈ $-8.53 Million
-0.866x -113.10%
2016-12-31 ₩24.35 Billion
≈ $16.50 Million
₩-9.90 Billion
≈ $-6.71 Million
-0.406x +84.40%
2015-12-31 ₩2.89 Billion
≈ $1.96 Million
₩-7.54 Billion
≈ $-5.11 Million
-2.605x -950.52%
2014-12-31 ₩-21.68 Billion
≈ $-14.69 Million
₩-6.64 Billion
≈ $-4.50 Million
0.306x --

About Qurient Co. Ltd

KQ:115180 Korea Biotechnology
Market Cap
$881.75 Million
₩1.30 Trillion KRW
Market Cap Rank
#9679 Global
#276 in Korea
Share Price
₩37300.00
Change (1 day)
-5.09%
52-Week Range
₩9950.00 - ₩50900.00
All Time High
₩50900.00
About

Qurient Co., Ltd., a biotech company, engages in the research and development of drugs to address unmet medical needs in Korea and internationally. The company's pipeline products include Q301, a topical 5LO inhibitor, which is in Phase II clinical trial for the treatment of atopic dermatitis; and Telacebec (Q203), Cyt bc1 Inhibitor, that is in Phase II to treat Mycobacterial Infections, such as … Read more